A small clinical trial of nilotinib in people with Parkinson’s disease finds that the cancer drug is reasonably safe and holds promise as a therapy.
A small clinical trial of nilotinib in people with Parkinson’s disease finds that the cancer drug is reasonably safe and holds promise as a therapy.